Answers are grounded in this paper and cite their sources.
Inhibition of AKR1C3 restores osimertinib sensitivity in nonsmall cell lung cancer with the C797S mutation, suggesting new treatment strategies.
Resistance to Osimertinib via the EGFR C797S mutation is a major challenge in the treatment of nonsmall cell lung cancer (NSCLC). Combining Osimertinib with SG-55, a novel selective AKR1C3 inhibitor, effectively reverses this resistance, restoring sensitivity in NSCLC cells with the C797S mutation. This highlights AKR1C3 inhibition in overcoming antitumor drug resistance for further preclinical investigation.
No takes yet. Share an insight, caveat, or question.
Wei Li (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: